GLP1R and stroke disorder: Clinical trials evaluating GLP-1 receptor agonists, such as the LEADER trial for liraglutide and the SUSTAIN-6 trial for semaglutide, demonstrated reductions in cardiovascular death, nonfatal myocardial infarction, and stroke.